Meta-Analysis
Copyright ©The Author(s) 2015.
World J Gastroenterol. Feb 28, 2015; 21(8): 2522-2533
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2522
Table 1 Characteristics of included studies in quadruple
Ref.RegionPublicationParticipantsH. pylori infection Initial diagnosis ⁄re-checkingInventions (duration)Total (treatment/contrlo)Follow-up (wk)Eradication rateJadad scores
Luo[36], 2002ChinaFull textNR1RUT/RUTOBAT 7v OBCM 745/45491% vs 56%1
Chi et al[37], 2003TaiwanFull textDyspeptic patientsHistology or culture/UBTOBAT 7v OBAM 750/50678% vs 58%3
Cheon et al[20], 2006South KoreaFull textPeptic ulcerHistology or RUT or UBT/UBTPBAT 7v PBMT 725/29516% vs 66%2
Uygun et al[40], 2008TuekryFull textNon-ulcer dyspeptic patientsHistology/histology and RUTLBAT 14 v LBAM or LBMT 14100/20060 d75% vs 73%2
Wu et al[45], 2011TaiwanFull textNRRUT and histology or culture or UBTEBTA 7 v EBTM 758/62862% vs 81%3
Chen et al[46], 2011ChineseFull textPeptic ulcer and chronic gastritisUBT/UBTOATF 14/OBAC 1460/60492% vs 90%2
Hu et al[23] , 2012TaiwanAbstractNRNR/UBTRATM 10, /RBTM, 1046/47≥ 483% vs 87%2
Liang et al[55], 2013ChinaFull textFunctional dyspeptic patients and peptic ulcerUBT/UBTLBAT 14/LBTF, LBTM and LBAF 14105/319683.8% vs 91.5%3
Our data1ChinaDuodenal pepticRUT/UBTRBAT 10/RBAC 1077/75485.7% vs 81.3%
1Unpublished data. NR: Not reported; UBT: Urea breath test; RUT: Rapid urease test; O: Omeprazole; A: Amoxicillin; T: Tetracycline; B: Bismuth; C: Clarithromycin; M: Metrodinazole; P: Pantoprazole; E: Esomeprazole; L: Lansoprazole; D: Doxycycline; F: Furazolidone; Le: Levofloxacin; RBC: Ranitidine bismuth citrate.
Table 2 Characteristics of included studies in triple
Ref.RegionPublicationParticipantsH. pylori infection Initial diagnosis⁄re-checkingInventions (duration)Total (treatment/control)Follow-up (wk)Eradication rate by ITTJadad scores
Laine et al[33] 1995United StatesFull textVolunteers with H. pylori infectionUBT/UBTOAT 14 vs OA 1430/30430% vs 50%3
Perri et al[24], 2003ItalyFull textNRUBT/UBTRBCAT 7 vs PLA or PBMT 760/1204-685% vs 73.3%3
Uygun et al[21], 2007TurkeyFull textNon-ulcer Dyspeptic patientsHistology and UBT/UBTRBCAT 14 vs RBCAC or RBCMT 14100/200658% vs 58%3
Chuah et al[50], 2012TaiwanFull textPeptic ulcer disease or gastritisRUT/RUT and histology or UBTEAT 14 vs EALe 1464/64875% vs 78%3
Zhao[17], 2013ChinaFull textpeptic ulcer and chronic gastritisNR/UBTPAT 7/PAC or PAM or PAF or PALe 734/13830 d94% vs 73%1
NR: Not reported; UBT: Urea breath test; RUT: Rapid urease test; O: Omeprazole; A: Amoxicillin; T: Tetracycline; B: Bismuth; C: Clarithromycin; M: Metrodinazole; P: Pantoprazole; E: Esomeprazole; L: Lansoprazole; D: Doxycycline; F: Furazolidone; Le: Levofloxacin; RBC: Ranitidine bismuth citrate.
Table 3 Characteristics of included studies in sequential treatment
Ref.RegionPublicationParticipantsH. pylori infection Initial diagnosis⁄re-checkingInventions (duration)Total (treatment/contrlo)Follow-up (wk)Eradication rate and PJadad scores
Uygun et al[41], 2008TurkeyFull textNon-ulcer dyspepsiaUBT and histology/UBTPA 7-PMT 7 vs PAC 14150/150672% vs 58%3
Nadir et al[44], 2011TurkeyFull textNon-ulcer dyspepsiaHistology/UBTLA 7-LMT 7 vs LAC 1460/120672% vs 54%2
Demir et al[47], 2011TurkeyFull textNon-ulcer Dyspeptic patientsUBT/UBTPA 7-PMT 7 vs PAC 1457/29456% vs 59%3
Kadayifci et al[51], 2012TurkeyFull textNon-ulcer Dyspeptic patientsUBT and histology/UBTLA 7-LCT 7 vs LA 7-LCM 7100/100472% vs 61%2
UBT: Urea breath test; RUT: Rapid urease test; O: Omeprazole; A: Amoxicillin; T: Tetracycline; B: Bismuth; C: Clarithromycin; M: Metrodinazole; P: Pantoprazole; E: Esomeprazole; L: Lansoprazole; D: Doxycycline; F: Furazolidone; Le: Levofloxacin; RBC: Ranitidine bismuth citrate.
Table 4 Studies not included in meta-analysis
Ref.RegionPublicationParticipantsH. pylori infection Initial diagnosis⁄re-checkingInventions (duration)CasesFollow-up (wk)Eradication rate by ITTFirst or second or three line therapy1
Graham et al[22], 1993United StatesFull textPeptic ulcerUBT and histology/UBT and histologyBAT 1416443%1
Lobo et al[19], 1994United KingdomFull textNRhistology or culture /histology and cultureOAT 21 vs BT 28+M 1417/26458% vs 65%1
Auriemma et al[34], 2001ItalyAbstractNRNR/UBTOAT 763NR77.3%2
Perri et al[35], 2002ItalyFull textDyspepsiaHistology and RUT/UBTLAT 7 vs RBCAT 7 vs LAD 789/88/874-635% vs 20% vs 36%1
Cammarota et al[25], 2004ItalyFull textNRCulture/UBTOBTA 789891%3
Sezgin et al[38],2007TurkeyFull textDyspepsia or peptic ulcerHistology and RUT and UBT/UBTPA 7-PMT 732450%1
Buzás et al[39], 2008HungaryFull textDuodenal ulcerhistology and RUT/UBTPATN 14 vs PATB 1422/19662% vs 55%3
Akyildiz et al[42], 2009TurkeyFull textNRHistology and RUT/UBTRBCAT 14/RBCAT 1458/57634.5% vs 36.8%1
Cetinkaya et al[26], 2010TurkeyFull textNonulcer dyspepsiaHistology/UBTPA 5- PTM 9 vs PA5-PATM 956/56682%/79%1
Ataseven et al[43], 2010TurkeyFull text2-type Diabetes mellitus with H. pyloriHistology and RUT/UBTPA 7-PTM 738458%1
Zhang[49], 2012ChinaFull textNRRUT and UBT/UBTEBAT1201 mo93%2
Tursi1 et al[52], 2012ItalyFull textpeptic ulcer or gastritis or duodenitisNR/RUT or UBTPPI+A 5 - PPI+Le+T 51191 mo67%3
Uygun et al[53], 2012TurkeyFull textnonulcerdyspepsiaHistology/UBTPBA 7 - PBTM 714245 d81%1
Kadayifci et al[48], 2012TurkeyFull textnon-ulcerdyspepsiaHistology and UBT/UBTEBAT 14/EATM 14100/100679%/74%1
Liou et al[54], 2013TaiwanFull textNRUBT or two of RUT, histology and cultureEA 7- EMC 7 vs EA 7-EMT 7 vs EA 7 - EMLe 719/65/51≥ 680%/71%/92%3
1Indicates first-line treatment for H. pylori; Indicates second-line treatment; Indicates third-line treatment. NR: Not reported; UBT: Urea breath test; RUT: Rapid urease test; O: Omeprazole; A: Amoxicillin; T: Tetracycline; B: Bismuth; C: Clarithromycin; M: Metrodinazole; P: Pantoprazole; E: Esomeprazole; L: Lansoprazole; D: Doxycycline; F: Furazolidone; Le: Levofloxacin; RBC: Ranitidine bismuth citrate.